GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (UKEX:MRK) » Definitions » Cyclically Adjusted PS Ratio

Merck (UKEX:MRK) Cyclically Adjusted PS Ratio : 6.42 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Merck Cyclically Adjusted PS Ratio?

As of today (2024-05-24), Merck's current share price is ₴4844.00. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₴754.78. Merck's Cyclically Adjusted PS Ratio for today is 6.42.

The historical rank and industry rank for Merck's Cyclically Adjusted PS Ratio or its related term are showing as below:

UKEX:MRK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.17   Med: 4.34   Max: 6.58
Current: 6.37

During the past years, Merck's highest Cyclically Adjusted PS Ratio was 6.58. The lowest was 3.17. And the median was 4.34.

UKEX:MRK's Cyclically Adjusted PS Ratio is ranked worse than
86.69% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.115 vs UKEX:MRK: 6.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's adjusted revenue per share data for the three months ended in Mar. 2024 was ₴248.704. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₴754.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Merck's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted PS Ratio Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.39 4.79 4.39 5.85 5.44

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 5.85 5.14 5.44 6.42

Competitive Comparison of Merck's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.



Merck Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merck's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4844.00/754.78
=6.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Merck's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=248.704/131.7762*131.7762
=248.704

Current CPI (Mar. 2024) = 131.7762.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 148.708 100.560 194.871
201409 145.455 100.428 190.859
201412 145.673 99.070 193.765
201503 131.943 99.621 174.531
201506 137.704 100.684 180.229
201509 142.457 100.392 186.992
201512 145.595 99.792 192.259
201603 133.626 100.470 175.263
201606 141.564 101.688 183.451
201609 151.679 101.861 196.225
201612 146.196 101.863 189.129
201703 136.796 102.862 175.249
201706 144.721 103.349 184.528
201709 151.857 104.136 192.164
201712 153.277 104.011 194.193
201803 148.548 105.290 185.917
201806 155.686 106.317 192.968
201809 161.660 106.507 200.015
201812 167.467 105.998 208.194
201903 166.657 107.251 204.768
201906 182.253 108.070 222.233
201909 193.320 108.329 235.162
201912 65.029 108.420 79.038
202003 189.864 108.902 229.745
202006 147.922 108.767 179.214
202009 172.711 109.815 207.251
202012 172.807 109.897 207.211
202103 167.740 111.754 197.792
202106 180.044 114.631 206.972
202109 208.037 115.734 236.873
202112 213.925 117.630 239.653
202203 251.383 121.301 273.092
202206 230.432 125.017 242.891
202209 236.025 125.227 248.370
202212 217.698 125.222 229.093
202303 227.771 127.348 235.692
202306 237.505 128.729 243.128
202309 251.455 129.860 255.166
202312 230.925 129.419 235.130
202403 248.704 131.776 248.704

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merck  (UKEX:MRK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merck Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (UKEX:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (UKEX:MRK) Headlines